Ellerson Group Inc. ADV Sells 5,600 Shares of Pfizer Inc. (NYSE:PFE)

Ellerson Group Inc. ADV lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,422 shares of the biopharmaceutical company’s stock after selling 5,600 shares during the period. Pfizer makes up 2.4% of Ellerson Group Inc. ADV’s investment portfolio, making the stock its 18th largest holding. Ellerson Group Inc. ADV’s holdings in Pfizer were worth $3,274,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $28,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Finally, Noble Wealth Management PBC bought a new position in shares of Pfizer in the fourth quarter worth approximately $31,000. Institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Stock Performance

PFE opened at $26.71 on Friday. The firm has a market cap of $151.35 billion, a P/E ratio of 18.94, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a 50 day simple moving average of $26.30 and a two-hundred day simple moving average of $27.24. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The company’s revenue was up 24.7% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.44%. Pfizer’s dividend payout ratio is currently 121.99%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $33.00 target price on shares of Pfizer in a research note on Monday, February 10th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.